These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12214139)

  • 1. Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors.
    Wilde JT
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():9-12. PubMed ID: 12214139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.
    Leissinger CA; Becton DL; Ewing NP; Valentino LA
    Haemophilia; 2007 May; 13(3):249-55. PubMed ID: 17498073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
    Barthels M
    Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T.
    Penner JA
    Haemophilia; 1999 Sep; 5 Suppl 3():1-9. PubMed ID: 10597382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FEIBA safety profile in multiple modes of clinical and home-therapy application.
    Luu H; Ewenstein B
    Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies.
    Négrier C; Lienhart A; Numerof R; Stephens D; Wong WY; Baghaei F; Yee TT
    Haemophilia; 2013 May; 19(3):e143-50. PubMed ID: 23282031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
    Valentino LA
    Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review.
    Lloyd Jones M; Wight J; Paisley S; Knight C
    Haemophilia; 2003 Jul; 9(4):464-520. PubMed ID: 12828680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience.
    Tjønnfjord GE
    Haemophilia; 2004 Sep; 10 Suppl 2():41-5. PubMed ID: 15385045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.
    Zanon E; Milan M; Gamba G; Ambaglio C; Saggiorato G; Spiezia L; Montani N; Prandoni P
    Thromb Res; 2015 Dec; 136(6):1299-302. PubMed ID: 26505666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
    Smith OP
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
    Ingerslev J; Sørensen B
    Br J Haematol; 2011 Oct; 155(2):256-62. PubMed ID: 21895627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seventeen years' experience with Autoplex/Autoplex T: evaluation of inpatients with severe haemophilia A and factor VIII inhibitors at a major haemophilia centre.
    White GC
    Haemophilia; 2000 Sep; 6(5):508-12. PubMed ID: 11012694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F; Moussard C; Allain JP
    Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
    Leissinger CA
    Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
    Economou M; Teli A; Tzantzaroudi A; Tsatra I; Zavitsanakis A; Athanassiou-Metaxa M
    Haemophilia; 2008 Mar; 14(2):390-1. PubMed ID: 18194305
    [No Abstract]   [Full Text] [Related]  

  • 19. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
    Tarantino M; Aledort L
    Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.